120 results
Page 3 of 6
6-K
EX-99.1
2ewu7d24
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
EX-99.1
9u8m8aq 74usy6s
17 Dec 21
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:15am
6-K
EX-99.1
p5h 2ucftl6
13 Dec 21
ObsEva Appoints Will Brown as Chief Financial Officer
7:00am
6-K
EX-99.1
lee7s9i36dvnaz32
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
6-K
EX-99.2
5f1 e4a8t13
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.1
2f65m 7jsy
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.3
dson3 65f8xy7cyj0
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
EX-99.1
n7hq76f
29 Oct 21
ObsEva Announces Management Change
5:24pm
6-K/A
EX-99.2
4o4oooqbgfaluw 9bc
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K/A
EX-99.5
ir0mc2 k3
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K/A
EX-99.1
5l434 t0bfpf
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.1
r6e9f1sfa8 87
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
4r2y3zoy4p66
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.2
aricq07ftxzbe883ndgt
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.5
bn7sdxa
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.1
rpdgyi
27 Jul 21
Current report (foreign)
6:12am
6-K
EX-99.1
ox7feuy5f5gp2wwy0
20 May 21
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of
6:30am
6-K
EX-99.1
pf06o2a
6 May 21
ObsEva appoints Clive Bertram as Chief Commercial Officer
6:05am
6-K
EX-99.3
avzr97v 53
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
EX-1.1
90o0gqki01
5 Mar 21
Current report (foreign)
8:15am